aec / bc02
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2020 (NCT04239313)
Timeline
Indications
Studied for
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05284812 | Phase 2 | Feb 10, 2022 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT04239313 | Phase 1 | Feb 28, 2020 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 2 | 2 | 2 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1